Update on the Management of ABCA4 Retinopathy (Stargardt Disease) Authors: Deepika C Parameswarappa, Dhanashree Ratra, Goura Chattannavar, Srikanta Kumar Padhy Published: 2026 ABSTRACT AbstractABCA4-associated retinopathies (Stargardt disease) are the most common inherited macular dystrophy and a leading cause of early onset central vision loss. Biallelic pathogenic variants in the ABCA4 gene cause impaired clearance of retinoid byproducts, leading to toxic bisretinoid accumulation, retinal pigment epithelium dysfunction, and progressive photoreceptor degeneration. Clinical presentation and disease progression are highly heterogeneous, largely influenced by genotype, age at onset, and environmental modifiers. Current management remains supportive and includes low-vision rehabilitation and counseling. Recent advances in molecular genetics, retinal imaging, and translational science have substantially expanded the therapeutic pipeline for ABCA4 retinopathy. Disease-modifying strategies under active investigation include visual-cycle modulation, deuterated vitamin A analogs, retinol-binding protein antagonists, gene augmentation and editing approaches, antisense oligonucleotides, and cell-based regenerative therapies. Several pharmacologic agents have demonstrated promising structural outcomes in clinical trials, while gene-based and regenerative approaches continue to evolve amid challenges related to gene size, delivery efficiency, and long-term safety. Optogenetic therapy has emerged as a gene-agnostic option for functional vision restoration in advanced disease stages. This review provides an integrated overview of ABCA4 retinopathy, summarizing disease mechanisms, current management strategies, emerging therapies, and the evolving clinical trial landscape. Emphasis is placed on stage-adapted treatment paradigms, appropriate monitoring endpoints, and the potential role of combination therapies. Ongoing innovation and precision-based approaches offer cautious optimism for durable disease modification and functional preservation in this currently untreatable condition.Keywords: ABCA4 retinopathy (Stargardt disease); lipofuscin/A2E; Visual cycle modulation; Gene therapy (dual AAV, ASOs, genome editing); RPE cell therapy; Optogenetics Key Summary Points ABCA4 retinopathy (Stargardt disease) is the most prevalent inherited macular dystrophy and a major cause of early onset blindness, yet it remains without an approved therapy capable of altering its natural history.Elucidation of ABCA4-mediated retinoid transport and lipofuscin-driven toxicity has reshaped the therapeutic landscape, catalyzing precision strategies that target distinct stages of disease biology—from upstream metabolic modulation to genetic correction and downstream functional rescue.Pharmacologic visual-cycle modulators have demonstrated meaningful reductions in structural progression, while dual-AAV and RNA-based gene therapies show compelling preclinical evidence of lipofuscin suppression and are advancing toward clinical validation.Regenerative cell therapies and gene-agnostic optogenetic platforms extend therapeutic opportunity into advanced stages, reframing treatment goals from disease modification to restoration of visual function.Convergence of molecular therapeutics, stage-adapted trial design, and biomarker-driven monitoring signals a paradigm shift toward integrated, precision-based care for inherited retinal degeneration, positioning ABCA4 retinopathy at the forefront of translational ophthalmology. Introduction ABCA4 retinopathy, commonly known as Stargardt disease (STGD1), is the most prevalent inherited macular dystrophy and a leading cause of early onset central vision loss. The disorder arises from biallelic pathogenic variants in the ABCA4 gene, which encodes a photoreceptor-specific ATP-binding cassette transporter responsible for the clearance of retinoid intermediates generated during the visual cycle. Loss of ABCA4 function results in accumulation of toxic bisretinoids and lipofuscin within the retinal pigment epithelium, triggering oxidative stress, complement activation, and progressive photoreceptor degeneration [1]. Clinically, ABCA4 retinopathy presents with gradual loss of central vision, impaired color discrimination, and delayed dark adaptation, typically manifesting in childhood or early adulthood. The disease course is heterogeneous, influenced by age at onset, allelic severity, modifier variants, and environmental factors, yet often culminates in legal blindness during the most productive years of life [2]. Current clinical management is limited to supportive measures, as no approved therapy exists to meaningfully alter disease progression, underscoring a substantial unmet therapeutic need. Recent advances in molecular genetics, disease modeling, and retinal imaging have provided critical insights into disease pathophysiology, enabling the identification of actionable therapeutic targets. These developments have catalyzed a rapidly evolving translational pipeline encompassing visual cycle modulators, gene augmentation and editing strategies, antisense oligonucleotides, and regenerative therapies [3]. This review covers current management approaches and emerging treatment strategies for ABCA4 retinopathy, with a focus on translational progress, clinical trial outcomes, and future directions toward disease-modifying and precision-based interventions. Methods A focused narrative review of ABCA4-associated retinopathy was conducted to synthesize current evidence on disease mechanisms and emerging therapeutic strategies. A systematic literature search was performed across PubMed/MEDLINE, Embase, and ClinicalTrials.gov to identify relevant studies published up to December 2025. The search strategy combined controlled vocabulary (e.g., MeSH and Emtree terms) and free-text keywords, including: “ABCA4” OR “Stargardt disease” AND “visual cycle modulation” OR “gene therapy” OR “cell-based therapy” OR “optogenetics” OR “clinical trials”. Reference lists of included articles and relevant reviews were manually screened to identify additional studies. Eligibility criteria included peer-reviewed observational studies, interventional clinical trials, preclinical/translational research, and relevant qualitative reports addressing ABCA4-associated disease mechanisms, functional outcomes, or therapeutic interventions. Studies were restricted to those published in English. Exclusion criteria comprised conference abstracts without full text, non-peer-reviewed sources, studies not specific to ABCA4-associated retinopathy, and reports lacking sufficient methodological detail or outcome data. Study selection was performed through title and abstract screening followed by full-text review, with emphasis on relevance to clinical translation and methodological rigor. Given the narrative nature of the review, a formal systematic review protocol was not applied; however, ENTREQ (Enhancing Transparency in Reporting the Synthesis of Qualitative Research) principles were followed where applicable to improve transparency and reporting clarity. To enhance interpretability, included evidence was qualitatively appraised and categorized according to study design and level of evidence (e.g., preclinical studies, early phase clinical trials, randomized controlled trials, and real-world observational studies). Greater weight was given to well-designed clinical trials and studies with validated functional or structural endpoints, while preclinical findings were interpreted in a translational context. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval and informed consent were not required. Overview of Disease Mechanism ABCA4 belongs to the subfamily-A of ATP-binding cassette (ABC) transporters and is localized to the disc membranes of rod and cone outer segments [4, 5]. Pathogenic variants in the retina-specific ATP-binding transporter gene (ABCR) were identified as a gene-specific defects for recessive Stargardt macular dystrophy [1]. The visual cycle is a cascade of molecular reactions that recycle all-trans retinal, produced after photobleaching of rhodopsin and cone opsins, into 11-cis retinal, enabling regeneration of visual photopigments (Fig. 1A). ABCA4 mediates the transport of 11-cis and all-trans N-retinylidene-phosphatidylethanolamine (N-ret-PE) across disc membranes [6] (Fig. 1B and C). A Visual cycle: all-trans retinal from rhodopsin bleaching is reduced by RDH8, transported to the RPE via IRBP, esterified by LRAT, converted by RPE65 isomerohydrolase to 11-cis retinol, oxidized by 11-cis retinol dehydrogenases to 11-cis retinal, and returned to photoreceptors for rhodopsin regeneration. B Excess retinal in the photoreceptor discs reacts with PE to form N-c-R-PE, which is transported by ABCA4 to the cytoplasmic side and isomerizes to N-t-R-PE. Hydrolysis releases all-trans retinal, which is reduced by RDH8 to all-trans retinol. C All-trans retinal generated by rhodopsin bleaching is either directly reduced to all-trans retinol or reacts with PE to form N-t-R-PE, which is transported by ABCA4 to the cytoplasmic side, hydrolyzed to release all-trans retinal, and reduced by RDH8 to all-trans retinol. RDH8 retinol dehydrogenases, RPE retinal pigment epithelium, IRBP interphotoreceptor retinoid-binding protein, LRAT by lecithin:retinol acyltransferase, PE phosphatidylethanolamine, N-c-R-PE N-cis-retinylidene-phosphatidylethanolamine, N-t-R-PE to N-trans-retinylidene-phosphatidylethanolamine, RBP4 retinol binding protein-4 Biallelic pathogenic variants in ABCA4 gene impair retinal-activated ATPase activity and N-ret-PE transport leading to protein misfolding with mislocalization [7–9]. This disrupts retinal clearance of toxic products from photoreceptor disc membranes, leading to retinoid accumulation and formation of toxic bisretinoids [10, 11]. These compounds accumulate as lipofuscin in RPE cells and, through photooxidation, generate toxic byproducts that drive cell death [12]. (Fig. 1D). Understanding the molecular basis of ABCA4 function lays the basis for the development of therapies aimed at reducing toxic bisretinoid accumulation by modulating vitamin A transport or inhibiting visual cycle enzymes. Current and Upcoming Management Approaches Supportive Care Supportive care remains a foundational component in the management of ABCA4 retinopathy, particularly in the absence of universally available disease-modifying therapies. Comprehensive counseling and lifestyle guidance play a critical role in optimizing residual visual function, and supporting long-term quality of life. Patients should be counseled regarding modifiable environmental and behavioral risk factors that may influence disease progression. Excessive light exposure has been implicated in accelerating photoreceptor and retinal pigment epithelium damage through photo-oxidative mechanisms, particularly in the context of lipofuscin accumulation [13]. Patients are therefore advised to adopt practical light-management strategies, including use of ultraviolet- and blue-light-filtering spectacles, wide-brimmed hats in bright environments, and avoidance of unnecessary high-intensity light exposure [10, 14, 15]. Experimental Abca4 knock-out models show that bright light accelerates bisretinoid (A2E) accumulation, complement activation, and photoreceptor loss, supporting a phototoxic contribution to disease progression beyond the intrinsic genetic defect [16]. Smoking cessation should be strongly emphasized, as tobacco-related oxidative stress may exacerbate retinal degeneration and has been associated with poorer outcomes across retinal diseases [17–19]. Counseling on modifiable risk factors emphasizes avoiding intake of vitamin A supplementation, as ABCA4 dysfunction impairs retinoid clearance, leading to toxic lipofuscin (A2E) accumulation. Low dietary intake (< 600 µg RAE/day) correlates with better visual acuity [20, 21]. Lifestyle adjustments like promoting Mediterranean-style diets low in saturated fats to reduce inflammation are recommended [21, 22]. Low-vision aids and rehabilitation strategies are essential for managing ABCA4 retinopathy, where progressive central vision loss necessitates optimization of residual function. Magnifying handheld lenses, electronic magnifiers, screen readers, high-contrast materials, telescopes, and wearable artificial intelligence visual assistants enhance reading, mobility, and daily activities. In a study by Das et al., involving 97 patients with Stargardt disease (mean age 23.7 ± 13.1 years), the selection of low-vision aids was seen to be significantly influenced by age, presenting visual acuity, disease stage, duration of disease, as well as educational level and occupational visual demands [23]. Older patients (> 40 years) required higher magnification and preferred half-eye spectacles. Advanced disease stages were associated with greater magnification needs (p = 0.03, R2 = 0.11), and longer disease duration showed a positive correlation with magnification requirement (p = 0.03, R2 = 0.049) [23]. With advancing deterioration in the vision, the appropriateness of the prescribed low vision device needs to be periodically reassessed. In younger patients with small-sized scotoma, biofeedback training using microperimetry can be attempted to train a preferred retinal locus for eccentric fixation [24]. Fixation stability, visual acuity as well as retinal sensitivity was seen to improve with the biofeedback training. Early referral to low-vision specialists improves outcomes, with multidisciplinary support addressing psychosocial needs. Pharmacologic Therapies: Chaperons and Small Molecules Currently, there are no approved therapies for Stargardt disease. However, several pharmacological agents are actively undergoing investigation [25]. These therapies are directed towards reducing accumulation of toxic bisretinoids either by modulating vitamin A transport or inhibiting enzymes in the visual cycle (Fig. 2). Retinoid cycle and sites of pharmacological therapeutic intervention. Light converts 11-cis retinal to all-trans retinal in photoreceptors. All-trans retinal is reduced to all-trans retinol, transported to the RPE, and regenerated to 11-cis retinal by RPE65. Excess all-trans retinal forms bisretinoids (A2E) that accumulate as lipofuscin in the RPE. Deuterated vitamin A (gildeuretinol) slows A2E formation; RPE65 inhibition (emixustat) reduces 11-cis retinal regeneration; RBP4 antagonism (tinlarebant) limits retinol delivery from blood; and metformin is shown as a potential modulator of lipofuscin accumulation ALK-001 (Gildeuretinol; Alkeus Pharmaceuticals) is currently the most promising pharmacologic candidate for ABCA4 retinopathy. As a deuterated vitamin A analog, it increases molecular stability, thereby slowing the dimerization reactions that form toxic bisretinoids such as A2E while maintaining normal visual cycle activity. The TEASE-1 study (Tolerability and Effects of ALK-001 in STGD) was the first prospective trial designed to test whether altering vitamin A dimerization could change disease trajectory in Stargardt disease [26]. In this phase 2 study (n = 50, ages 18–60), ALK-001 was well tolerated and significantly reduced atrophic lesion progression by 21.6% over 24 months compared with placebo (p < 0.001) [27]. TEASE-2 (n = 80) is an ongoing trial in patients with intermediate disease severity. TEASE-3 extended evaluation to presymptomatic adolescents (n = 7, ages 13–18) [28]. It demonstrated sustained tolerability over 24 months. The treated participants maintained retinal structure and function, whereas their older symptomatic, untreated siblings continued to deteriorate, supporting a disease-modifying effect of ALK-001. TEASE-4 is an ongoing open-label extension enrolling participants from all previous TEASE studies to evaluate long-term safety and efficacy. Tinlarebant (LBS-008; Belite Bio) is a selective antagonist of retinol-binding protein 4 (RBP4) engineered to reduce the amount of vitamin A transported to the retina. By lowering circulating RBP4, it reduces retinol entry into the RPE and thereby curtails production of toxic bisretinoids [29]. In a phase 1b/2 study in adolescents with Stargardt disease (ages 12–18), tinlarebant showed good safety and overall tolerability [30, 31]. At 15 months, trial findings indicated a tendency towards slower enlargement of areas of questionably decreased autofluorescence (QDAF) and maintenance of visual acuity. Subsequent 24-month phase 2 results confirmed encouraging structural benefits. In 42% (5 out of 12) patients, no new atrophic lesions characterized as definitely decreased autofluorescence (DDAF) developed. While among the remainder, DDAF lesion expansion was reduced by about 50% compared with matched historical controls (p < 0.001) [31]. Collectively, these data support tinlarebant as a promising disease-modifying therapy for early Stargardt disease. In September 2025, Belite Bio announced the successful completion of the phase 3 DRAGON trial, a global, multicenter, randomized, double-masked, placebo-controlled study in 104 adolescents (ages 12–18) [32]. Tinlarebant has been granted breakthrough therapy designation by the Food and Drug Administration (FDA). Emixustat (Acucela; Kubota Vision) is an orally administered small molecule that blocks the activity of RPE65. This inhibition lowers production of the visual chromophore 11-cis-retinal and consequently reduces generation of toxic bisretinoids. Although early phase trials showed encouraging biological and clinical signals, the phase 3 SeaSTAR study in Stargardt disease failed to demonstrate a significant benefit of emixustat on the primary outcome of macular atrophy progression [33]. Another molecule that modulates the visual cycle indirectly by limiting delivery of retinol to the RPE is fenretinide, a synthetic retinoid. Under physiologic conditions, retinol is bound to RBP4, which is required for transport because free retinol is rapidly cleared by the kidneys due to its small molecular size. Fenretinide acts as an RBP4 antagonist, competing with retinol for binding sites on RBP4, thereby decreasing the fraction of retinol that reaches the RPE and enters the visual cycle. Since visual cycle activity depends on adequate retinol availability, this reduction is expected to downregulate chromophore production and in turn lessen the accumulation of toxic bisretinoid byproducts. In a mouse model characterized by excessive A2E buildup in RPE cells, fenretinide produced a dose-dependent reduction in circulating retinol and effectively halted further A2E accumulation [34]. However, in a clinical trial of patients with geographic atrophy, oral fenretinide (ReVision Therapeutics) failed to produce a statistically significant slowing of geographic atrophy (GA) lesion enlargement compared with placebo-treated controls. Another agent under investigation is soraprazan (Katairo GmbH), which is intended to facilitate clearance of lipofuscin from the RPE. Although its exact mode of action has not been fully elucidated, it is hypothesized that soraprazan binds excess aldehydes and fragments them into smaller components that cells can more readily eliminate [25]. Beyond modulation of the retinoid cycle, metformin has emerged as a promising candidate to address dysregulated lipid metabolism in Stargardt disease [35]. Metformin, a widely used oral drug for type 2 diabetes, improves lipid metabolism and stimulates autophagy by activating AMP-activated protein kinase (AMPK). In Abca4-/- mouse models, metformin treatment reduced lipofuscin deposition and photoreceptor degeneration, reinforcing its potential utility in Stargardt disease [36]. On this basis, the National Eye Institute is conducting a clinical study enrolling patients with Stargardt disease to assess the efficacy and safety of metformin in this setting (https://clinicaltrials.gov/study/NCT04545736). In this study, oral metformin is initiated at 500 mg once daily and gradually titrated as tolerated to a target dose of up to 2000 mg per day. Avacincaptad pegol (Izervay; Astellas) is an intravitreally administered inhibitor of complement component C5 that has received FDA approval for the treatment of geographic atrophy. It is now being explored for additional retinal indications, including Stargardt disease. Preclinical work indicates that lipofuscin buildup in the RPE can trigger complement activation, ultimately leading to cell death [37]. In a pivotal phase 2/3 AMD study, avacincaptad pegol significantly slowed the rate of geographic atrophy enlargement, although treated eyes showed a higher incidence of macular neovascularization compared with sham controls [38]. A phase 2b clinical trial in Stargardt disease is currently in progress to assess its potential benefits. Table 1 gives an overview of the current pharmacological treatments under research for ABCA4 retinopathy. Table 1Emerging pharmacological treatments for ABCA4 retinopathyDrugMechanismPhaseKey structural/functional outcomesSafety/tolerabilityClinical trial ID(s)Status (Jan 2026)EmixustatRPE65 isomerase inhibitorPhase 340.8% slower atrophy growth in small lesions over 24 monthsMild delay in dark adaptationNCT03772665 (SeaSTAR)Development ongoing; post-hoc analyses and subgroup exploration following SeaSTARFenretinideRBP4 antagonist; lowers serum retinolPhase 2~ 50% reduction in urinary A2E (extrapolated from AMD data)Rod recovery delayNCT00429936Limited advancement; no active late-phase Stargardt trialsTinlarebant (LBS-008)Non-retinoid RBP4 inhibitorPhase 336% reduction in lesion growth in adolescentsExcellent tolerability, particularly in pediatric populationNCT05244304 (DRAGON)Phase 3 met primary endpoint; FDA Breakthrough Therapy Designation; regulatory interactions ongoingALK-001 (Gildeuretinol)Deuterated vitamin A; slows A2E dimerizationPhase 321–28% slower lesion growth over 2 yearsNo nyctalopia; ~ 98% treatment retentionNCT04239625 (TEASE-3), NCT06123623 (SAGA)TEASE-3 positive interim analysis; SAGA phase 3 enrollingAvacincaptad pegol (Zimura)Complement C5 inhibitorPhase 2bPreservation of ellipsoid zone (ongoing analysis)Safety profile established from AMD trialsNCT03364153Active/enrolling for Stargardt diseaseMetforminEnhances RPE macroautophagyPhase 1/2Lipofuscin clearance (preclinical evidence)Standard oral tolerability profileNCT04545736Recruiting / early clinical evaluation Emerging pharmacological treatments for ABCA4 retinopathy Pharmacological chaperones are molecules aimed to stabilize misfolded ABCA4 proteins, thereby reducing the accumulation of toxic bisretinoids and lipofuscin in the retinal pigment epithelium and slowing disease progression. Many disease-causing variants in the ABCA4 gene are missense variants that result in protein misfolding, instability, and retention within the endoplasmic reticulum. In addition, misfolded ABCA4 proteins show impaired trafficking and fail to localize to the plasma membrane. Pharmacological chaperones are designed to bind and stabilize these mutant ABCA4 proteins, thereby promoting correct folding, improving cellular trafficking to the plasma membrane, and reducing endoplasmic reticulum accumulation [39–41]. In vitro studies have demonstrated the usefulness of small corrector molecules such as VX-809 (lumacaftor), which rescued trafficking of ABCA4 mutants in G1961E, A1038V, R1108C and R1129C [41, 42]. Co-transfection of heat shock protein (Hsp27) along with VX-809 further increased protein expression, producing a marked synergistic rescue effect, with approximately a five-fold increase in ABCA4 mutant protein levels, particularly in the G1961E variant. Another molecule, QR-1011, an antisense oligonucleotide, has been shown to correct splicing defects in ABCA4 variants (c.5461−10T > C, c.5461−8T > G, and c.5584 + 6T > C), leading to improved RNA levels and better protein trafficking [43]. Additionally, studies have demonstrated temperature sensitivity of ABCA4 protein folding, with cells cultured at lower temperatures (30 °C) showing improved protein folding, stability, and trafficking compared with physiological temperature. The same study reported that two corrector candidates; 4-phenylbutyric acid (4-PBA) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) enhanced protein trafficking to the cell surface in in vitro experiments [44]. Validation in animal models and further translational studies are awaited. Gene-Based Therapies Gene-based therapies for Stargardt disease aim to provide a normal functional copy of the ABCA4 gene or to correct the existing gene defect [45, 46]. By doing so, the underlying pathophysiology is targeted, with the goal of preventing or reversing the accumulation of abnormal A2E lipofuscin products, thereby reducing photoreceptor and retinal pigment epithelium degeneration [47, 48]. The major hurdle noted until a decade ago in treating this most common gene defect (ABCA4) using gene therapy approaches was its size and the choice of a suitable vector. The size of ABCA4 is quite large to be carried by the most widely and successfully used adeno-associated viral (AAV) vectors [45, 49]. The cargo capacity of AAV is approximately 4.7 kb, whereas the ABCA4 gene has a 6.8-kb-long coding sequence [45]. Other viral vectors with larger cargo capacity include lentiviral vectors. Lentiviral vectors belong to the retroviral vector group and have a cargo capacity of approximately 8 kb, making them suitable for a large gene such as ABCA4. A few trials using a lentiviral approach were conducted; however, the efficacy in reducing A2E deposition and providing structural outcome evidence has not been conclusive [19, 50]. Additionally, when compared with AAV, lentiviral vectors can integrate into the host genome, have a higher risk of mutagenesis or genotoxicity, and limit transduction capacity. On the other hand, the advantages of AAV over lentiviral vectors include being largely non-pathogenic, not integrating into the host genome, demonstrated safety and efficacy in the majority of trials, robust transduction, retinal cell-specific tropism, and lower immunogenicity [45]. Hence, various reports explored alternative ways of using AAV to enable carriage of the ABCA4 gene, leading to the emergence of the dual-vector concept. The dual-vector concept evolved through three methods: overlapping regions, trans-splicing approaches, and hybrid dual-vector strategies [47, 51–54]. All three approaches showed evidence of reduced abnormal A2E products accumulation in animal models. The concept of hybrid dual AAV vectors has gained more popularity, wherein the correct DNA sequence of the large ABCA4 gene is incorporated into two or more inverted terminal repeat (ITR)-mediated AAV vectors [54, 55]. Once delivered into the target tissue, these vectors reconstitute the complete corrected DNA sequence within retinal cells as a single functional therapeutic unit and can express and transduce the therapeutic effects of a normally functioning ABCA4 gene. Although small and large animal models have shown the efficacy of dual-vector AAV methods in reducing abnormal A2E products accumulation, results from human clinical trials are awaited [56–59]. Some non-viral approaches for Stargardt gene-based therapy include antisense oligonucleotides and nanoparticles [60, 61]. Antisense oligonucleotides (ASOs) are RNA modulators with complementary targets to the primary defect intended to be corrected. They can act through splice modulation or exon skipping. For ABCA4-related Stargardt disease, a few studies have demonstrated the usefulness of ASOs in removing pseudoexons or aberrantly activated exons [62–64]. A phase 1/2 clinical trial program evaluating protein splicing (SpliceBio, SB-007/ASTRA) and mRNA trans-splicing (VeonGen, VG801) therapies has been initiated (https://www.fightingblindness.org/news/stargardt-disease-research-advances). Another non-viral approach of nanoparticles has been designed to carry the entire gene in a plasmid form. Polyethylene glycol-substituted polylysine (CK30PEG) first showed useful evidence of a nanoparticle approach capable of packaging large ABCA4 DNA constructs, achieving sustained full-length ABCA4 expression for 2–8 months after subretinal injection in ABCA4 knockout mice, and was associated with reduced RPE lipofuscin accumulation [60]. More recently, amino-lipid ECO (1-aminoethyl) iminobis(N-(oleoylcysteinyl-1-amino-ethyl) propionamide) nanoparticles have been evaluated. Subretinal delivery of ECO nanoparticles carrying full-length ABCA4 with a rhodopsin promoter led to markedly elevated ABCA4 mRNA levels in treated ABCA4 knockout eyes and evidence of reduced A2E accumulation over time [65–67] (Table 2 lists the ongoing gene therapy trials at various phases). Table 2Gene therapy trials in ABCA4-Associated Stargardt DiseaseTrail/sponsor nameProduct nameTrail ID (clinicaltrials.gov)PhaseStudy detailsSTELLAR; Ascidian Therapeutics, Inc.ACDN-01NCT064673441/2To evaluate the safety, tolerability, and evidence of biological effect of low, medium, and high doses of ACDN-01 delivered subretinally. ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editorASTRA; Splice BioSB-007NCT06942572Phase 1/2To evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007Vector; dual AAV8 geneGARDian3: Ocugen OCU410STNCT05956626Phase 2/3Randomized, outcome assessor-masked, multicenter study of subretinal AAV5 containing human Retinoic Acid-Related Orphan Receptor Alpha (RORα)SanofiSAR422459NCT01736592Phase 2Long-term follow-up of patients who received EIAV-ABCA4 gene therapy (SAR422459) in previous study TDU13583VeonGen Therapeutics GmbHVG801NCT070023981/2To evaluate the safety and preliminary efficacy of subretinal VG801Zhongshan Ophthalmic Center, Sun Yat-sen UniversityZVS106eNCT07241169Early phase 1To explore the preliminary safety and clinical efficacy of ZVS106e subretinal injectionViral vectors used; rAAV8START; HuidaGene Therapeutics Co., LtdHG005NCT07063251Early phase 1Dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of subretinal HG005West China HospitalJWK006NCT06300476Phase 1/2Dose-escalation clinical study, to evaluate the safety, tolerability, and preliminary effectiveness of subretinal JWK006 Gene therapy trials in ABCA4-Associated Stargardt Disease To evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 Vector; dual AAV8 gene To explore the preliminary safety and clinical efficacy of ZVS106e subretinal injection Viral vectors used; rAAV8 Genome-editing methods: These use various types of nucleases to edit existing defects and restore the normal variant at a specific genomic region. The most promising approach is clustered regularly interspaced short palindromic repeats (CRISPR) genome editing, which represents a viable strategy for STGD1, wherein correcting at least the most common variants may allow treatment of a major subgroup of patients [68]. However, results in animal models are yet to be demonstrated. Both ASOs and CRISPR are mainly mutation-specific, and a major challenge remains addressing the large number of reported ABCA4 variants. There is evolving role of RNA exons editing(ACDN-01) and modifier gene therapy(Ocugen, OCU410ST) in Stargardt disease (https://www.fightingblindness.org/news/stargardt-disease-research-advances). Cell-Based and Regenerative Therapies Cell-based and regenerative therapies have been explored as structural and functional rescue strategies in ABCA4 retinopathy, particularly in eyes with established retinal pigment epithelium loss and secondary photoreceptor degeneration [69]. The translational premise rests on replacing dysfunctional RPE to restore metabolic support to residual photoreceptors or, alternatively, providing neurotrophic support through progenitor or mesenchymal cell-based approaches [70]. Subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) has demonstrated a favorable safety profile across phase 1/2 studies in atrophic age-related macular degeneration and Stargardt disease, with no evidence of tumorigenicity, ectopic tissue formation, or immune-mediated rejection during medium- to long-term follow-up [71] These findings have been replicated across geographically distinct cohorts, including three-year follow-up in Asian patients and independent phase I studies employing optical coherence tomography-guided delivery, further confirming procedural feasibility and long-term tolerability [72, 73]. Persistent subretinal pigmentation consistent with graft survival supports biological durability; however, functional outcomes have been variable and generally modest. Although treated eyes more frequently showed stabilization or limited improvement in best-corrected visual acuity than untreated fellow eyes, durable superiority over contralateral controls was not observed [71]. Five-year follow-up in early stage Stargardt disease confirmed long-term biosafety but revealed heterogeneous visual trajectories, with outcomes strongly influenced by baseline retinal structure and autofluorescence patterns [74]. In contrast, small non-randomized studies using non-lineage-committed stem cell populations, including adipose- or bone marrow-derived cells, have reported short-term visual improvements, likely mediated by paracrine effects rather than durable cellular replacement [75, 76]. Collectively, these findings suggest that RPE replacement alone may be insufficient in advanced disease and highlight the importance of earlier intervention or combinatorial strategies to achieve sustained visual benefit. Subretinal RPE progenitor programs such as OpRegen have reported encouraging structural preservation signals in macular degeneration cohorts, though Stargardt-specific efficacy remains preliminary [77]. In contrast, intravitreal retinal progenitor approaches, exemplified by jCell, are designed to exert paracrine neuroprotective effects rather than direct cellular integration and may therefore be more relevant in earlier disease stages with residual photoreceptor viability [78, 79]. From a translational perspective, several barriers limit clinical impact: incomplete functional integration, uncertain long-term survival within a persistently bisretinoid-toxic microenvironment, immunologic considerations requiring perioperative immunosuppression, and surgical risks inherent to subretinal delivery [80]. Crucially, regenerative strategies do not correct the underlying ABCA4 defect, rendering transplanted cells susceptible to the same pathogenic milieu. As such, current evidence supports positioning cell-based therapies as adjunctive modalities, most rationally combined with upstream disease-modifying approaches such as gene augmentation or editing (“Gene-Based Therapies”) and visual-cycle modulation (“Pharmacologic Therapies: Chaperons and Small Molecules”) to reduce ongoing retinoid toxicity and enhance graft durability (Table 3). Table 3Summary of cell-based and regenerative therapy approaches in ABCA4 retinopathyTherapy categoryCell source/productRoute of administrationStudy (year)Study designNo. of patients (Stargardt)Primary outcomeKey findingshESC-derived RPE (cell suspension)Human embryonic stem cell-derived RPESubretinalSong et al., Stem Cell Reports, 2015 [81]Phase 12SafetyFeasible in Asian patients; limited efficacy conclusions due to small samplehESC-derived RPE (cell suspension)Human embryonic stem cell-derived RPESubretinalSchwartz et al., Lancet, 2015 [71]Phase 1/2, open-label9SafetyNo tumorigenicity or immune rejection; graft pigmentation observed; modest, variable BCVA changeshESC-derived RPE (cell suspension)Human embryonic stem cell-derived RPESubretinalMehat et al., Ophthalmology, 2018 [82]Phase 1/2, dose escalation12SafetyWell tolerated up to higher doses; no consistent functional benefitMesenchymal stem cells (adipose-derived)Autologous adipose-derived MSCsSuprachoroidalOner et al., Cell Reprogramming, 2018 [75]Phase 2, nonrandomized4Safety and exploratory efficacyShort-term improvements in BCVA and electrophysiology; uncontrolled designhESC-derived RPE (cell suspension)Human embryonic stem cell-derived RPESubretinalLi et al., Cell Proliferation, 2021 [74]Phase 17Long-term safetyFive-year follow-up confirmed safety; transient stabilization common; long-term outcomes heterogeneoushESC-derived RPE (cell suspension)Human embryonic stem cell-derived RPESubretinalSung et al., Br J Ophthalmol, 2021 [72]Phase 13Long-term safetyNo serious adverse events over 3 years; visual acuity improved in one patient and stabilized in othersBone marrow-derived stem cells (SCOTS)Autologous bone marrow-derived cellsMixed periocular, intraocular, systemicWeiss and Levy, Medicines, 2021 [76]Open-label case series17 patients (34 eyes)Visual acuityMajority showed improvement or stabilization; heterogeneous delivery routes; no controlsiPSC-derived RPE (enabling technology)Induced pluripotent stem cell-derived RPE—Sharma et al., STAR Protocols, 2022 [83]Methods / protocol–Manufacturing reproducibilityRobust generation of mature, polarized RPE monolayers supporting future clinical usehESC-derived RPE (cell suspension; OCT-guided)Human embryonic stem cell-derived RPESubretinalFernandes et al., Retina, 2023 [73]Phase 1–Safety and feasibilityNo inflammation, rejection, or tumor formation; BCVA changes not significantRPE retinal pigment epithelium, OCT optical coherence tomography, hESC human embryonic stem cell Summary of cell-based and regenerative therapy approaches in ABCA4 retinopathy RPE retinal pigment epithelium, OCT optical coherence tomography, hESC human embryonic stem cell Combination and Adjunctive Therapies The heterogeneous and progressive nature of ABCA4 retinopathy increasingly necessitates combination and adjunctive therapeutic strategies that address distinct but converging disease mechanisms across different stages of retinal degeneration. Monotherapy approaches—whether genetic, pharmacologic, or regenerative—are unlikely to provide durable benefit across the full disease spectrum, particularly given cumulative lipofuscin toxicity, oxidative stress, inflammatory signaling, and irreversible photoreceptor loss. A rational combination strategy involves pairing gene-based therapies with pharmacologic modulation of the visual cycle. Gene augmentation or genome editing strategies for ABCA4-associated retinopathy are fundamentally designed to restore functional ABCA4 protein activity within photoreceptor outer segments, thereby reconstituting physiologic clearance of all-trans-retinal derivatives and reducing the formation of toxic bisretinoids such as A2E [84]. By addressing the underlying transport defect, these approaches are expected to attenuate ongoing lipofuscinogenesis and slow the progressive accumulation of bisretinoid byproducts within the RPE. In preclinical models, this mechanistic rationale has been substantiated. In Abca4−/− and Abca4/Rdh8 double knockout mice, subretinal delivery of dual AAV vectors encoding full-length ABCA4 resulted in significant reductions in fundus autofluorescence and ocular A2E levels—approximately 40% and 38%, respectively, compared with sham-treated controls—demonstrating that restoration of ABCA4 function can attenuate ongoing lipofuscin accumulation [85]. Similarly, large-animal models, including STGD1 pig models, have shown reductions in lipofuscin burden following dual AAV-mediated gene supplementation, with favorable photoreceptor transduction profiles observed in nonhuman primates [59]. Adjunctive use of visual-cycle modulators or retinoid-binding agents may therefore reduce metabolic stress on photoreceptors and retinal pigment epithelium, potentially enhancing the durability and functional impact of gene therapy—particularly in early to intermediate disease stages. Such upstream–downstream targeting exemplifies a precision-based multimodal approach [47]. Adjunctive neuroprotective strategies also play an important supportive role [86]. Antioxidant therapies, light management, and lifestyle interventions, including avoidance of excessive light exposure and high-dose vitamin A supplementation—remain integral to current clinical care. Although their disease-modifying capacity is limited, these measures may synergize with emerging therapies by mitigating secondary retinal injury. Anti-inflammatory and complement-modulating strategies are under investigation, though robust clinical evidence in Stargardt disease remains sparse. Optogenetic Therapy as an Adjunctive Strategy Optogenetic therapy represents a gene-agnostic adjunctive approach for advanced ABCA4 retinopathy, particularly in eyes with extensive photoreceptor and retinal pigment epithelium loss where conventional gene or cell-based therapies are unlikely to be effective [87]. By conferring light sensitivity to surviving inner retinal neurons, optogenetics bypasses the outer retina and directly targets residual retinal circuitry [88]. Table 4 highlights available optogenetic platforms for ABCA4 retinopathy. Table 4Optogenetic pipeline for advanced ABCA4 retinopathy (Stargardt disease)Therapy/platformSponsorMechanism of actionClinical trial (NCT number)Status (2026)MCO-010Nanoscope TherapeuticsSensitizes bipolar cells to ambient light via AAV2; no goggles requiredNCT05417126(STARLIGHT)Phase 3 registrational study dosing following positive Ph2 dataRTx-021Ray TherapeuticsTargets retinal ganglion cells(RGCs) to create a new light-sensing layerNCT06460844(ENVISIONa)IND-enabling phase; specifically targeting Stargardt and GAGS030GenSight BiologicsOpsin delivery to RGCs; requires visual interface goggles for stimulationNCT03326336(PIONEER)Phase 1/2a; currently dose-escalating with expansion plans for StargardtBS01Bionic SightOpsin delivered to RGCs + visual processing device to mimic neural codeNCT04278131Phase 1/2; evaluating safety and light/motion detection in IRDsRST-001Allergan / AbbVieChannelrhodopsin-2 delivered to RGCs to restore basic light sensitivityNCT02556736Early phase (phase 1/2); long-term follow-up and evaluation ongoingAAV2 adeno-associated virus serotype 2, BCVA best-corrected visual acuity, ChR2 channelrhodopsin-2, FDA Food and Drug Administration (US), GA geographic atrophy, IND investigational new drug, IRD inherited retinal disease, MCO multi-characteristic opsin, NCT national clinical trial identifier, OBC ON-bipolar cell, RGC retinal ganglion cell, RMAT regenerative medicine advanced therapy designationaRTx-015 is currently in the ENVISION trial; RTx-021 is the derivative platform specifically optimized for central macular diseases like Stargardt. While MCO-010 focuses on OBCs to utilize the retina's natural signal-processing layers, other platforms like GS030 and RTx-021 target RGCs, which are typically the most resilient cells in end-stage ABCA4 retinopathy. The choice of therapy may eventually depend on the degree of inner retinal remodeling in the individual patient Optogenetic pipeline for advanced ABCA4 retinopathy (Stargardt disease) AAV2 adeno-associated virus serotype 2, BCVA best-corrected visual acuity, ChR2 channelrhodopsin-2, FDA Food and Drug Administration (US), GA geographic atrophy, IND investigational new drug, IRD inherited retinal disease, MCO multi-characteristic opsin, NCT national clinical trial identifier, OBC ON-bipolar cell, RGC retinal ganglion cell, RMAT regenerative medicine advanced therapy designation aRTx-015 is currently in the ENVISION trial; RTx-021 is the derivative platform specifically optimized for central macular diseases like Stargardt. While MCO-010 focuses on OBCs to utilize the retina's natural signal-processing layers, other platforms like GS030 and RTx-021 target RGCs, which are typically the most resilient cells in end-stage ABCA4 retinopathy. The choice of therapy may eventually depend on the degree of inner retinal remodeling in the individual patient The most advanced optogenetic program in Stargardt disease is MCO-010, developed by Nanoscope Therapeutics, which utilizes a synthetic, broadband-sensitive, multi-characteristic opsin designed to transduce ON-bipolar cells via intravitreal delivery [89, 90]. Targeting bipolar cells offers theoretical advantages over retinal ganglion cell-based approaches, including higher cellular density, closer proximity to native visual processing pathways, and the potential for improved spatial resolution. In the open-label phase 2 STARLIGHT trial, six adults with genetically confirmed Stargardt disease and advanced vision loss received a single intravitreal injection of MCO-010 and were followed for 48 weeks [89]. The therapy demonstrated an acceptable safety profile, with no serious adverse events, retinal detachment, endophthalmitis, or treatment-limiting inflammation. Mean best-corrected visual acuity improved by approximately 5–7 ETDRS letters over 48 weeks, with greater gains observed when combined with a wearable low-vision magnifier. Notably, participants with atrophy confined to the macula achieved more robust improvements (> 10 ETDRS letters), whereas responses were attenuated in those with panretinal atrophy. Improvements were also observed in visual field sensitivity and patient-reported outcomes related to reading, contrast, and color perception, supporting a functional benefit beyond acuity alone. However, several limitations warrant caution. The study was limited by small sample size, open-label design, lack of sham control, and evidence of contralateral effects in fellow eyes, likely related to intravitreal vector diffusion, complicating efficacy attribution. This effect was also reported in earlier studies [91–94]. Importantly, optogenetic therapy does not slow disease progression, reduce lipofuscin burden, or restore native phototransduction, positioning it as a functional rescue strategy rather than a disease-modifying intervention. Comparative Perspective and Translational Readiness Despite rapid advances, the therapeutic landscape for ABCA4-associated retinopathy remains heterogeneous in both evidentiary strength and translational maturity. Gene-based strategies offer the most compelling disease-modifying rationale by directly addressing the underlying ABCA4 defect; however, their clinical translation is constrained by vector capacity limitations, allelic heterogeneity, and the absence of robust efficacy data from late-phase trials. Cell-based approaches, particularly hESC-derived RPE transplantation, have demonstrated reproducible safety and procedural feasibility, yet functional benefits have been modest, variable, and strongly dependent on baseline retinal integrity, with limited evidence of sustained superiority over natural history. In contrast, optogenetic therapies provide a mutation-agnostic strategy for functional restoration in advanced disease, but current evidence is restricted to small, early phase, largely uncontrolled studies with short follow-up, and observed gains remain modest and frequently device-dependent. Importantly, these approaches do not address the underlying pathophysiology or halt disease progression. Taken together, no single modality currently offers comprehensive or durable disease control, underscoring the likelihood that stage-specific or combinatorial strategies will be required. Accordingly, most emerging therapies should still be regarded as investigational, and their near-term clinical impact remains uncertain pending validation in larger, controlled studies with longer-term outcomes. Genotype–Phenotype Integration and Therapeutic Implications A defining feature of ABCA4-associated retinopathy is its marked genotype–phenotype heterogeneity, which critically influences age at onset, disease trajectory, and residual photoreceptor integrity. Allelic severity spans a broad spectrum—from early onset, rapidly progressive cone–rod dystrophy associated with null variants to milder, late-onset phenotypes linked to hypomorphic missense mutations. This variability has direct therapeutic implications. Disease-modifying strategies, including visual-cycle modulation and gene-based therapies, are most likely to be effective in earlier stages, where sufficient photoreceptor structure and metabolic activity are preserved. In contrast, variant-specific approaches, such as antisense oligonucleotides or RNA editing, offer precision targeting but are inherently limited to defined genetic subsets, restricting scalability in a highly heterogeneous population. In advanced disease, where photoreceptor loss is substantial, gene augmentation alone is unlikely to restore function, shifting the therapeutic focus toward cell-based and optogenetic strategies aimed at structural replacement or functional bypass. However, outcomes remain contingent on baseline retinal architecture and the persistent toxic microenvironment, including lipofuscin accumulation and retinal remodeling. Collectively, these considerations emphasize that ABCA4 retinopathy cannot be approached as a uniform entity. Instead, effective management will require stage-adapted, genotype-informed therapeutic frameworks, with future clinical trials increasingly incorporating genotype stratification and biomarker-guided patient selection to optimize efficacy and interpretability. Clinical Trials Landscape, Monitoring, and Treatment Response The current clinical-trials landscape in ABCA4 retinopathy is dominated by disease-modifying pharmacologic programs aimed at slowing progression in earlier-stage disease. Gene-replacement and cell-based regenerative strategies remain in early translational or early phase development, while optogenetics is emerging as an alternate function-restoration approach for patients with advanced photoreceptor loss. The overarching design challenge is that STGD1 progression is gradual and heterogeneous, with large inter-individual variability driven by genotype, age at onset, and baseline lesion characteristics—factors that can dilute treatment signals unless trials enrich for specific stages/phenotypes and apply sensitive endpoints. Accurate assessment of treatment response in ABCA4 retinopathy requires a rigorous, multimodal monitoring strategy, reflecting the disease’s slow progression, spatial heterogeneity, and evolving therapeutic goals. As interventions increasingly aim to modify disease biology rather than provide symptomatic benefit, emphasis has shifted toward objective biomarkers capable of detecting subtle but clinically meaningful change over time. Imaging biomarkers form the backbone of treatment evaluation. Fundus autofluorescence (FAF) remains the most widely adopted structural endpoint, enabling quantification of atrophic lesion and flecks size and growth rate, serving as a surrogate marker of retinal pigment epithelium loss [95]. Quantitative autofluorescence (qAF) offers additional sensitivity in earlier disease by providing a standardized measure of lipofuscin burden, particularly relevant for trials targeting the visual cycle [96–98]. Spectral-domain optical coherence tomography (SD-OCT) complements FAF by characterizing outer retinal integrity, including ellipsoid zone disruption, photoreceptor layer thinning, and RPE alterations, thereby facilitating structure–function correlations. En face OCT [99] and OCT angiography [100] further refine spatial assessment and are increasingly incorporated in longitudinal protocols. Functional outcome measures are essential to contextualize structural findings but must be selected judiciously. Best-corrected visual acuity (BCVA), while widely accepted by regulatory agencies, has important limitations. It primarily reflects foveal cone function and is assessed using high-contrast, static optotypes, making it relatively insensitive to parafoveal dysfunction, scotoma-related deficits, and small or localized changes, particularly in early disease. Moreover, BCVA is subject to ceiling effects in patients with preserved central vision and floor effects in advanced disease with established central macular atrophy, limiting its ability to capture disease progression across the full spectrum of ABCA4-associated Stargardt disease. Microperimetry has therefore emerged as a preferred functional endpoint, as it provides topographically resolved retinal sensitivity measurements that can be directly co-registered with structural imaging biomarkers, enabling more precise structure–function correlation [101–103]. Additional functional assessments may provide complementary information, particularly in advanced disease stages or in interventional trials such as optogenetics. Contrast sensitivity testing evaluates visual performance under low-contrast conditions and across mid-spatial frequencies, offering insights into aspects of vision that are highly relevant to everyday activities. Visual field testing, including standard automated perimetry or kinetic perimetry, enables characterization of localized or peripheral field loss, which may not be detected by central acuity measures. Dark adaptation testing assesses rod-mediated recovery kinetics following photobleaching and may serve as a sensitive biomarker of early dysfunction in diseases involving rod impairment. In parallel, patient-reported outcome measures (PROMs) addressing reading ability, visual function, and vision-related quality of life are increasingly recognized as indispensable for capturing clinically meaningful benefit from the patient perspective. Given the anticipated durability of gene, cell, and optogenetic therapies, long-term follow-up is imperative. Standardized imaging protocols, bilateral eye analyses, genotype–phenotype-based stratification, and extended safety surveillance are essential to distinguish true therapeutic effect from natural history. Harmonization of endpoints across trials will be critical to advancing translational insights into sustained clinical impact. Future Directions and Challenges The translation of emerging therapies for ABCA4 retinopathy into durable clinical benefit is constrained by several interrelated scientific and regulatory challenges. Foremost among these is the extensive allelic heterogeneity of the ABCA4 locus, which includes hundreds of pathogenic variants spanning missense, truncating, splice-site, and deep intronic changes [104, 105]. This complexity complicates variant classification, limits genotype-specific therapeutic targeting and necessitates robust functional assays to resolve variants of uncertain significance and refine genotype–phenotype correlations. A second major barrier is efficient delivery of large genetic payloads to photoreceptors. The ABCA4 coding sequence exceeds the packaging capacity of conventional adeno-associated viral vectors, prompting development of alternative strategies including dual-AAV systems, oversized AAV constructs, lentiviral vectors, ASOs and non-viral nanoparticle platforms. While preclinical studies demonstrate phenotypic rescue using several of these approaches, each presents trade-offs in transduction efficiency, cell-type specificity, durability of expression, and immunologic risk, also clinical evidence with patient data is pending, underscoring the need for further optimization before widespread clinical adoption [106]. Ethical and regulatory considerations further shape therapeutic development, particularly for irreversible gene and cell-based interventions. These include requirements for long-term safety surveillance, challenges related to pediatric enrolment, limitations on vector re-administration, and regulatory acceptance of surrogate structural endpoints as predictors of functional benefit. Looking forward, the field is converging on a stage-adapted therapeutic paradigm that integrates early disease modification via genetic or pharmacologic interventions with later-stage functional restoration strategies. Progress toward truly curative treatment will depend on coordinated advances in delivery technologies, biomarker validation, and rigorously designed clinical trials capable of linking molecular correction to sustained visual function. Conclusions The therapeutic landscape for ABCA4 retinopathy has evolved rapidly, moving beyond supportive care toward a diverse pipeline of pharmacologic, gene-based, regenerative, and optogenetic strategies. Advances in molecular genetics, retinal imaging, and translational trial design have enabled more precise targeting of disease mechanisms across different stages. However, significant barriers remain, including genetic heterogeneity, delivery challenges for large genes, and the need for validated long-term endpoints that link structural rescue to functional benefit. Despite these challenges, continued innovation and integration of precision medicine approaches offer a realistic and optimistic path toward durable disease modification and functional restoration for patients with ABCA4 retinopathy. Author Contributions Drs. Srikanta Kumar Padhy, Deepika C Parameswarappa, Dhanashree Ratra, and Goura Chattannavar conducted the literature search and drafted the manuscript. Dr. Srikanta Kumar Padhy assisted with conceptualization, study design, and manuscript editing. All authors reviewed and approved the final version of the manuscript. Funding No funding or sponsorship was received for this study or publication of this article. Data Availability Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Declarations Conflict of Interest Srikanta Kumar Padhy, Deepika C Parameswarappa, Dhanashree Ratra, and Goura Chattannavar have nothing to disclose. Ethical Approval This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval and informed consent were not required. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.